Treatment of a Salmonella-induced rapidly expanding aortic pseudoaneurysm involving the visceral arteries using the Cardiatis multilayer stent  by Reijnen, Michel M.P.J. & van Sterkenburg, Steven M.M.
From
Auth
Rep
R
(e
The
to
m
0741
Cop
http
105Treatment of a Salmonella-induced rapidly
expanding aortic pseudoaneurysm involving the
visceral arteries using the Cardiatis multilayer stent
Michel M. P. J. Reijnen, MD, PhD, and Steven M. M. van Sterkenburg, MD, Arnhem, The Netherlands
Treatment of infection-induced aortic aneurysms is among the greatest challenges nowadays of vascular surgery because
the use of prosthetic material is considered unsuitable. The Cardiatis multilayer stent (Cardiatis, Isnes, Belgium) is a ﬂow-
diverting bare stent with a proven efﬁcacy in peripheral and visceral artery aneurysms. We present a unique case of
a Salmonella serotype enteritidis-induced rapidly expanding aortic pseudoaneurysm with a penetrating ulcer that was
treated with the Cardiatis multilayer stent. At 18 months of follow-up, the patient was in good clinical condition, with
normalized C-reactive protein levels. Computed tomography angiography and 2-deoxy-2-[F18]-ﬂuoro-D-glucose-
positron-emission tomography/computed tomography showed a stable, mostly thrombosed aneurysm, with adequate
perfusion of the side branches and no remaining signs of infection. (J Vasc Surg 2014;60:1056-8.)The treatment of infection-induced aortic aneurysms is
complicated by the fact that prosthetic material cannot be
used. The femoral vein or a spiral vein constructed from the
great saphenous vein may both be considered as a conduit.
Despite advances in perioperative care, major surgery in these
patients, who often have extensive comorbidities, results in
a high morbidity and a mortality rate of up to 40%.1
Some small case series have described the feasibility of
endovascular repair of infectious arterial disease, especially
mycotic aneurysms.2-5 Endovascular repair, using a stent
graft, may provide time to optimize the patient’s condition
and act as a bridge to deﬁnitive surgery. Anatomic factors,
however, may limit the application of endografts for the
treatment of arterial aneurysms. The patient gave consent
to publish the data.
Flow-diverting stents have recently been designed to
reduce ﬂow velocity in the aneurysm sac and promote
thrombosis while maintaining ﬂow in the main artery and
branch vessels. In a recent review, Sfyroeras et al6
concluded that the initial clinical experience in the treat-
ment of visceral and peripheral aneurysms yields satisfactory
results in technical success, aneurysm thrombosis and
shrinkage, and in patency of branch vessels.
The Cardiatis multilayer stent (Cardiatis, Isnes,
Belgium) is a bare cobalt alloy self-expanding stent with
proven efﬁcacy in peripheral and visceral aneurysms.7 We
present a unique case of a Salmonella serotype enteritidis-
induced rapidly expanding aortic pseudoaneurysm with
a penetrating ulcer that was treated with the Cardiatis stent.the Department of Surgery, Rijnstate Hospital.
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6CASE REPORT
A 78-year-old male patient, with a medical history of insulin-
dependent diabetes mellitus, dyslipidemia, and a laparotomy for
a bowel perforation, was admitted to the hospital with fever,
weakness, chills, headache, and abdominal pain. He had a fever
of 39.5C, blood pressure of 103/62 mm Hg, a pulse of 102
beats/min, and a blood oxygen saturation of 86%. The blood
leukocyte count was 14.4 109/L, C-reactive protein (CRP)
was 140 mg/L, and the glomerular ﬁltration rate was 45 mL/min.
Sepsis, with an unknown cause, was diagnosed, and the
patient was treated with ceftriaxone (1000 mg, two times daily)
and amoxicillin (2000 mg, six times daily). A computed tomog-
raphy (CT) scan of the thorax and abdomen showed no focus of
the sepsis. Blood cultures demonstrated a Salmonella serotype
enteritidis (group D).
Owing to respiratory insufﬁciency, the patient was intubated
and ventilated from days 5 to 7 after admission. At day 20 after
admission, a 2-deoxy-2-[F18]-ﬂuoro-D-glucose positron emission
tomography (FDG-PET) fused with CT images was performed
because the patient developed progressive back pain, but it showed
no focal uptake. The blood leukocyte count and CRP levels had
normalized but rose again at day 27 to, respectively, 18.4 
109/L and 234 mg/L.
A new CT scan now showed a saccular aneurysm of the aorta,
located at the level of the superior mesenteric artery, with a maximal
diameter of 39 mm. Both renal arteries were located within the
aneurysm. A surgical reconstruction was considered, but the
patient was considered to be unﬁt for this major surgical procedure
because of his age and general condition. A CT scan 1 week later
showed the aneurysm diameter had increased to 56 mm, with signs
of an impending rupture, including the rapid growth and the pres-
ence of a penetrating ulcer (Fig 1). We decided to treat the patient
with a ﬂow-diverting stent to reduce pressure from the aneurysm
and maintain blood ﬂow through the visceral arteries.
The patient was operated on under local anesthesia. The right
femoral artery was exposed, and a 20F introduction sheath was
introduced in the aorta. Then a 28-  100-mm Cardiatis multi-
layer stent was inserted in the aorta, positioned under ﬂuoroscopy,
and deployed. A control angiography showed a good position of
Fig 1. A and B, A computed tomography (CT) angiography shows an aneurysm with a contained rupture at the level
of the visceral arteries.
Fig 2. A 2-deoxy-2-[F18]-ﬂuoro-D-glucose-positron-emission
tomography/computed tomography (FDG-PET/CT) scan 2
months after surgery shows focal uptake (arrows) in the aneu-
rysmal wall, with a standardized uptake value of 4.0.
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mesenteric artery, and the renal arteries.
The patient was discharged from the hospital on postoperative
day 8 with acetylsalicylic acid (80 mg, once daily), clopidogrel (75
mg, once daily), and ciproﬂoxacin (500 mg, twice daily) therapy.
At 2 months postoperatively, the blood leukocyte count and
the CRP level had normalized. A control FDG-PET/CT scan,
performed to assess any possible ongoing infection, however,
showed a focal uptake in the aneurysmal wall with a standardized
uptake value of 4.0 (Fig 2), supporting the infectious origin of this
aneurysm. At 18 months postoperatively, patient was in good clin-
ical condition, with a blood leukocyte count and CRP level within
normal reference ranges and a stable glomerular ﬁltration rate of
81 mL/min. The FDG-PET/CT scan demonstrated no signs of
residual infection, and CT angiography showed a stable, mostly
thrombosed, aneurysm with patent visceral arteries (Fig 3). The
antibiotic therapy was stopped, without recurrence of disease.
DISCUSSION
The use of ﬂow-diverting stents for aneurysms
involving vital side branches will remain a matter of debate
as long as their efﬁcacy and safety have not been completely
elucidated. In noninfected aneurysms, a fenestrated or
branched endograft should be the ﬁrst endovascular
consideration. In our patient, with a rapidly enlarging
aneurysm and a penetrating ulcer, the use of these endog-
rafts was not an option because they are custom made. This
may change in the near future because off-the-shelf devices
will be available soon. Moreover, their use would implicate
the implantation of graft material in an infected environ-
ment, and because our patient was unﬁt for open repair,
considering it as a bridge to deﬁnitive surgery was not an
option.
The use of the Cardiatis stent in an infected aneurysm
has not been described to date, neither has its use in
a contained ruptured aortic aneurysm. The absence of graft
material provided the opportunity for the stent to remain
in situ for life, without any signs of ongoing infection at
18 months. After insertion of the stent, the aneurysm stabi-
lized, without further expansion, indicating that the stentindeed reduced the pressure in the aneurysm immediately.
The side branches remained patent during follow-up, and
renal function was unaffected.
Flow-diverting stents were developed to reduce ﬂow
velocity within the aneurysm vortex while maintaining
laminar ﬂow within the main artery and side branches.6
Because these stents modulate ﬂow and do not seal, as
do covered stents, the goal is to promote thrombosis.
However, a thrombosed aneurysm does not preclude sac
pressurization, and the risk of rupture may still be present.
Therefore, sac shrinkage might be a more accurate marker
of aneurysm depressurization and prevention from rupture,
although further research is indicated to support this
hypothesis.
CONCLUSIONS
Despite the successful and life-saving treatment of our
patient, the use of ﬂow-diverting stents for complex aneu-
rysms should be limited only to those compassionate-use
cases without treatment alternatives. Further studies on
Fig 3. A and B, A computed tomography (CT) angiography 18 months after surgery shows a stable, mostly
thrombosed, aneurysm with patent visceral arteries.
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aneurysms are indicated to assess the position of these
stents in the treatment algorithms of aneurysmal disease.REFERENCES
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